Biotech Firm PsyBio Therapeutics Is Producing Psilocybin From Bacteria
PsyBio Therapeutics is harvesting the psychedelic compound psilocybin from a strain of bacteria instead of mushrooms.
Author: Jennifer Walker-Journey
Psychedelic Business Spotlight: June 4, 2021
This week in psychedelic business: Mindset Pharma’s new research, synthetic ibogaine, and the Western Hemisphere gets its first “smart shop.”
New York Bill Proposes State-Sponsored Psychedelic Research Institute
New York is looking to explore psychedelic research through the formation of a new institute to investigate the healing potential.
California Senate Passes Psychedelic Decriminalization Bill
California is poised to become the second U.S. state to decriminalize possession and use of psychedelics following Oregon.
Cybin Taps First-of-Its-Kind Device to Study Psychedelic Effects of Ketamine
A new device may help Cybin better understand the psychedelic impact of the drug ketamine on the human brain.
‘PSY’ Becomes First U.S.-Listed Psychedelic ETF
Defiance Next Gen Altered Experience ETF began trading Friday on the New York Stock Exchange under the symbol PSY.
Why Deepak Chopra Wants to Shift Public Perception About Psychedelics
Spiritual leader and healer Deepak Chopra is focused on bringing attention to psychedelics as a means to heal trauma.
Psychedelic Business Spotlight: May 28, 2021
This week in psychedelic business news: NeonMind’s Medical Advisory Board, Mynd’s public listing, and a new study supports novel use of DMT.
Attorneys General, Organizations, Specialists Sue DEA for Access to Psilocybin for Terminally Ill Patients
A coalition of activists, organizations, and attorneys general are suing the DEA on behalf of terminally ill patients seeking psilocybin treatment.
FDA Approves First-Ever MDMA Study for Therapist Volunteers to Better Treat PTSD Patients
The FDA has approved a novel study allowing therapists who treat PTSD to take MDMA to better understand the treatment benefits.
End of content
End of content